GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anacor Pharmaceuticals Inc (NAS:ANAC) » Definitions » Piotroski F-Score

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Anacor Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Anacor Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Anacor Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Anacor Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Anacor Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anacor Pharmaceuticals Piotroski F-Score Chart

Anacor Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 1.00 6.00 2.00 4.00

Anacor Pharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 3.00 1.00 4.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar16) TTM:Last Year (Mar15) TTM:
Net Income was -13.196 + -16.177 + -18.914 + -16.147 = $-64.43 Mil.
Cash Flow from Operations was -23.746 + -24.219 + -13.985 + -9.588 = $-71.54 Mil.
Revenue was 21.337 + 24.55 + 21.204 + 17.535 = $84.63 Mil.
Gross Profit was 20.657 + 23.959 + 19.208 + 16.606 = $80.43 Mil.
Average Total Assets from the begining of this year (Mar15)
to the end of this year (Mar16) was
(214.888 + 195.778 + 188.479 + 176.102 + 164.002) / 5 = $187.8498 Mil.
Total Assets at the begining of this year (Mar15) was $214.89 Mil.
Long-Term Debt & Capital Lease Obligation was $62.26 Mil.
Total Current Assets was $157.30 Mil.
Total Current Liabilities was $25.01 Mil.
Net Income was -24.508 + -31.342 + -10.124 + -12.961 = $-78.94 Mil.

Revenue was 2.931 + 3.955 + 9.642 + 15.264 = $31.79 Mil.
Gross Profit was 2.931 + 3.753 + 9.047 + 14.51 = $30.24 Mil.
Average Total Assets from the begining of last year (Mar14)
to the end of last year (Mar15) was
(156.921 + 137.631 + 158.633 + 205.919 + 214.888) / 5 = $174.7984 Mil.
Total Assets at the begining of last year (Mar14) was $156.92 Mil.
Long-Term Debt & Capital Lease Obligation was $60.81 Mil.
Total Current Assets was $186.28 Mil.
Total Current Liabilities was $40.69 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Anacor Pharmaceuticals's current Net Income (TTM) was -64.43. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Anacor Pharmaceuticals's current Cash Flow from Operations (TTM) was -71.54. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar15)
=-64.434/214.888
=-0.29984922

ROA (Last Year)=Net Income/Total Assets (Mar14)
=-78.935/156.921
=-0.50302381

Anacor Pharmaceuticals's return on assets of this year was -0.29984922. Anacor Pharmaceuticals's return on assets of last year was -0.50302381. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Anacor Pharmaceuticals's current Net Income (TTM) was -64.43. Anacor Pharmaceuticals's current Cash Flow from Operations (TTM) was -71.54. ==> -71.54 <= -64.43 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar15 to Mar16
=62.255/187.8498
=0.33140839

Gearing (Last Year: Mar15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar14 to Mar15
=60.808/174.7984
=0.34787504

Anacor Pharmaceuticals's gearing of this year was 0.33140839. Anacor Pharmaceuticals's gearing of last year was 0.34787504. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar16)=Total Current Assets/Total Current Liabilities
=157.298/25.012
=6.28890133

Current Ratio (Last Year: Mar15)=Total Current Assets/Total Current Liabilities
=186.277/40.691
=4.57784277

Anacor Pharmaceuticals's current ratio of this year was 6.28890133. Anacor Pharmaceuticals's current ratio of last year was 4.57784277. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Anacor Pharmaceuticals's number of shares in issue this year was 44.872. Anacor Pharmaceuticals's number of shares in issue last year was 43.432. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=80.43/84.626
=0.95041713

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=30.241/31.792
=0.95121414

Anacor Pharmaceuticals's gross margin of this year was 0.95041713. Anacor Pharmaceuticals's gross margin of last year was 0.95121414. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar15)
=84.626/214.888
=0.39381445

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar14)
=31.792/156.921
=0.20259876

Anacor Pharmaceuticals's asset turnover of this year was 0.39381445. Anacor Pharmaceuticals's asset turnover of last year was 0.20259876. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Anacor Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Anacor Pharmaceuticals  (NAS:ANAC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Anacor Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Anacor Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Anacor Pharmaceuticals (Anacor Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.
Executives
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anders D Hove director 30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
Graeme Bell officer: Executive VP and CFO 1324 WAVERLY ROAD, GLADWYNE PA 19035
Ryan T Sullivan officer: EVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Paul L Berns director, officer: President and CEO 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Mark Leschly director RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019
Geoffrey M. Parker officer: Executive Vice President & CFO 15 RIORDAN PLACE, MENLO PARK CA 94025
Paul H Klingenstein director 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301
David P Perry director, officer: President and CEO 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Rho Management Ventures Iv Llc 10 percent owner 124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Qp Lp 10 percent owner 124 DUNE RD, QUOGUE NY 11959
Rho Ventures Iv Lp 10 percent owner 124 DUNE ROAD, QUOGUE NY 11959

Anacor Pharmaceuticals (Anacor Pharmaceuticals) Headlines